US71880W5013 - Common Stock
Monday's after hours session: top gainers and losers
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company that develops...
Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics...
Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio...
Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new...
Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new...
Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new...
Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp....
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp....
Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2,...
Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17,...
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September...
September 16, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Phio’s INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts–(Newsfile Corp. – September 16, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune […]
Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp....
Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT August 29, 2024 8:30 AM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts–(Newsfile Corp. – August 29, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make […]
PHIO stock results show that Phio Pharma missed analyst estimates for earnings per share the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Phio Pharma (NASDAQ:PHIO) just reported results for the second quarter of 2024....
Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
August 14, 2024 5:00 PM EDT | Source: Phio Pharmaceuticals Corp. Marlborough, Massachusetts–(Newsfile Corp. – August 14, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the […]
Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8,...